FDA and EMA Overview: Cross-Disease Innovation

Gastrointestinal (GI) drug development is changing rapidly thanks to cross-disease immunology, targeted biologics, and increasingly nuanced regulatory expectations. This white paper explores FDA and EMA GI drug approval trends from 2019–2024, highlighting key therapeutic advances across IBD, celiac disease, eosinophilic GI disorders, IBS, and other major indications. It examines emerging endpoints, regulatory guidance, and cross-therapeutic innovation, giving you practical insights to inform smarter trial design, regulatory strategy, and development planning in an increasingly competitive market.